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Abstract
Rationale: The cardiovascular risk factor homocysteine is mainly bound to proteins in human plasma, and it has been
hypothesized that homocysteinylated proteins are important mediators of the toxic effects of hyperhomocysteinemia. It has
been recently demonstrated that homocysteinylated proteins are elevated in hemodialysis patients, a high cardiovascular
risk population, and that homocysteinylated albumin shows altered properties.
Objective: Aim of this work was to investigate the effects of homocysteinylated albumin - the circulating form of this amino
acid, utilized at the concentration present in uremia - on monocyte adhesion to a human endothelial cell culture monolayer
and the relevant molecular changes induced at both cell levels.
Methods and Results: Treated endothelial cells showed a significant increase in monocyte adhesion. Endothelial cells
showed after treatment a significant, specific and time-dependent increase in ICAM1 and VCAM1. Expression profiling and
real time PCR, as well as protein analysis, showed an increase in the expression of genes encoding for chemokines/cytokines
regulating the adhesion process and mediators of vascular remodeling (ADAM17, MCP1, and Hsp60). The mature form of
ADAM17 was also increased as well as Tnf-a released in the cell medium. At monocyte level, treatment induced up-
regulation of ICAM1, MCP1 and its receptor CCR2.
Conclusions: Treatment with homocysteinylated albumin specifically increases monocyte adhesion to endothelial cells
through up-regulation of effectors involved in vascular remodeling.
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Introduction
Hyperhomocysteinemia is a cardiovascular risk factor both in the
general population and in selected patient groups [1]. Previous
evidence showed that high homocysteine increases cell adhesion
and induces a proinflammatory state in the vessel wall by promoting
adhesion molecule expression and monocyte recruitment. In
particular, nuclear factor (NF)-kB activation and intercellular
adhesion molecule-1 (ICAM-1) stimulation have been shown [2].
High homocysteine also up-regulates monocyte chemoattractant
protein-1 (MCP1), interleukin-8 (IL-8) expression and secretion in
cultured human endothelial cells, smooth muscles cells, and
monocytes [3–6]. Also VCAM-1 expression is up-regulated [7].
Plasma homocysteine is mainly protein-bound, accounting for
.90% of total homocysteine (the remainder is found as free low-
molecular weight disulfide forms, including homocystine, that is
the homocysteine homodimer, and the homocysteine-cysteine
mixed disulfide). Only 1.5–4% of homocysteine in circulation is
present in its reduced form [8]. In many of previous studies,
homocysteine was simply added to cell culture medium in its
rather unphysiological free reduced form, thus rising concerns
about the possibility of artifactual effects mediated through
intervening formation of adducts with unpredictable protein
targets.
Under physiological conditions protein homocysteinylation
occurs through acylation of free amino groups (protein-N-
homocysteinylation), [9–11] and thiol group oxidation (protein-
S-homocysteinylation) [12].
It has been shown that hyperhomocysteinemia elicits its effects
on the vasculature mainly through homocysteinylated proteins
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31388[13]. In this respect, the functional properties of human serum
albumin are altered by homocysteine binding [14].
Homocysteine is commonly elevated in end-stage renal disease
(ESRD) patients on hemodialysis. This fact has attracted much
scientific interest, because of the high cardiovascular risk in these
patients, which is not exhaustively explained by the presence of
conventional risk factors and/or specific uremic toxins [15–17].
We recently showed that plasma protein homocysteinylation is
increased in uremic patients on hemodialysis and significantly
reduced, although not normalized, after folate supplementation
[14]. Concerning this issue, it can be mentioned that some
emphasis has been given in the literature on the role played by
protein-bound uremic toxins [18].
Protein homocysteinylation could be one of the principal
mediators of homocysteine toxicity, contributing to detrimental
structural and functional alterations at the molecular and cellular
level [19–21]. We therefore investigated the role of homocystei-
nylated albumin in eliciting cell adhesion, and monitored, starting
with a genome-wide approach, the expression of relevant
mediators in the adhesion process.
Methods
Synthesis and characterization of homocysteinylated
albumin
Homocysteinylated albumin was produced according to a
modification of the protocol published by Jakubowski [9] by
incubation with homocysteine thiolactone, determining the
formation of mainly N-homocysteinylated albumin, and a smaller
amount of S-homocysteinylated albumin. Homocysteinylated
albumin was HPLC-analyzed [14]. The N-homocysteinylated
albumin adduct was largely prevalent, while a very small amount
of S-homocysteinylated albumin. N-homocysteinylated albumin
concentrations used in the experiments were in the range of
0.80 nmol Hcy/mg albumin and, in order to facilitate comparison
with equivalent concentrations of circulating N-protein bound
homocysteine, are referred to as equivalent to concentration of
homocysteine in mol/L [14].
Homocysteinylated and unmodified albumin, purified by
reversed phase HPLC [14], were then characterized by electro-
spray mass spectrometry (ESI-MS) at the Pasarow Mass
Spectrometry Laboratory, UCLA, Los Angeles California,
U.S.A., as described by Puppione et al. [22]. Briefly, samples
were separated by size-exclusion chromatography and mass
spectrometry (ESI-MS) was performed using a triple quadrupole
instrument (API III, Applied Biosystems). Data were processed
using MacSpec 3.3, Hypermass and BioMultiview 1.3.1 software
(Applied Biosistems).
Cell cultures and treatments
Human endothelial cell line EAhy926 (ATCC) were grown in
high glucose concentration DMEM (Gibco), containing 10% fetal
bovine serum (Gibco), 1% glutamine, 1% penicillin/streptomycin
(Gibco), 1% fungizone (Gibco). Human monocytoid cell line U937
(ATCC) were grown in RPMI-1640 (Gibco) containing 10%
bovine fetal serum (Gibco), 1% penicillin/streptomycin (Gibco).
EAhy926 were incubated for 18 h, in the presence of 0.3 or
1.0 mmol/L Homocysteinylated albumin equivalent. Negative
controls were: a) cells incubated with unmodified human serum
albumin at a comparable protein concentration; b) cells incubated
without human serum albumin (i.e. untreated negative control); c)
cells incubated with carboxylmethylated human serum albumin, as
a control of differently-modified albumin at cysteine levels [23].
This control was included in order to rule out that any covalent
modification of human serum albumin could trigger adhesion,
irrespective of the kind of amino acid modification involved. Cells
incubated with Tnf-a 10 ng/ml for 4 h represented positive
controls.
U937 (ATCC) were incubated for 18 h, in the presence of
1.0 mmol/L Homocysteinylated albumin equivalent. Negative
controls were: a) cells incubated with unmodified human serum
albumin at a comparable protein concentration; b) cells incubated
without human serum albumin (i.e. untreated negative control).
Adhesion assay
EAhy926 were plated to 90% confluence in 24-well multiwell
plates and treated with homocysteinylated albumin or the
appropriate control for 18 h at 37uC. Treatment medium was
removed and saved; cells were washed once with incomplete
DMEM medium and 8610
5 monocytoid cells per well were co-
incubated, for 30 min at 37uC in the endothelial treatment
medium. Non-adherent U937 were removed by gently washing
thrice with PBS. Finally PBS containing 1% glutaraldehyde was
added to fix monocytes to the endothelial monolayer. Adherent
monocytes were counted directly using a Zeiss Axiovert 10
inverted photomicroscope (Carl Zeiss S.p.A., Milan, Italy) on three
randomly selected high magnification microscopic fields per well,
for each independent experiment. Ten independent experiments
were performed. Results were expressed as both mean of the
absolute number of adherent monocytes per field, and percentage
of adherent monocytes relevant to samples treated with Tnf-a
(100% adhesion).
Table 1. Amplification conditions and primer pairs for PCR
experiments.
MCP1 (NM_002982.3) 95uC for 30 sec, 58uC for 30 sec, 72uC for 30 sec
59-CAGCAGCAAGTGTCCCAAAG-39
59-GAGTGAGTGTTCAAGTCTTCGG-39
ICAM1 (NM_000201) 95uC for 30 sec, 62uC for 30 sec, 72uC for 30 sec
59-GGTGTATGAACTGAGCAATGTG-39
59-TGGCAGCGTAGGGTAAGG-39
ADAM17 (NM_003183) 95uC for 30 sec, 55uC for 30 sec, 72uC for 30 sec
59-GTATCTGAACAACGACACCTG-39
59-CTCCTGGCACTTCTTCTGG-39
NRP1 (NM_003873) 95uC for 30 sec, 60uC for 30 sec, 72uC for 30 sec
59-GGAACTTGGTGGATGAATGTGATG-39
59-CTCTGATTGTATGGTGCTGTCTATG-39
TFP1 (NM_006287) 95uC for 30 sec, 57uC for 30 sec, 72uC for 30 sec
59-ATAACTCCCTGACTCCGCAATC-39
59-TGGCACGACACAATCCTCTG-39
VCAM1 (NM_001078) 95uC for 30 sec, 63uC for 30 sec, 72uC for 30 sec
59-TCTACGCTGACAATGAATCCTG-39
59-CTTGACTGTGATCGGCTTCC-39
CCR2 (NM_001123396) 95uC for 30 sec, 54uC for 30 sec, 72uC for 30 sec
59-TTCTTCATCATACTCCTGACAATCG-39
59-AGCAAACACAGCCACCAACC-39
Hsp60 95uC for 30 sec, 55uC for 30 sec, 72uC for 30 sec
Quatitect primer assay (Quiagen)
All conditions are relevant to real time PCR except for VCAM1, where tradition
PCR has been employed. 35 amplification cycles have been performed.
doi:10.1371/journal.pone.0031388.t001
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RNA extraction was performed, on endothelial cells, treated
with homocysteinylated albumin, utilizing Trizol reagent (Invitro-
gen), according to the supplier’s protocols. RNA concentration
was measured by NanoDrop UV/VIS micro- spectrophotometry
(ND-1000; NanoDrop Technologies, Wilmington, DE, USA).
Expression profile
Microrray hybridization and data analysis were carried out
using Human Genome U133A Plus 2.0 GeneChip arrays
(Affymetrix, Santa Clara, CA, U.S.A.), containing 54000 hybrid-
ized genes, essentially as described by Calin et al [24].
Transcriptome data were compliant with the MIAME (Minimum
Information About a Microarray Experiment) standard and
registered in suitable format on the ArrayExpress Archive
database (http://www.ebi.ac.uk/microarray-as/ae/).
Real time PCR
cDNA synthesis from 1 mg of total RNA was made using the
QuantiTect reverse transcriptase kit (Qiagen, Life Sciences, Milan,
Italy). Amplifications were performed with the iCycler thermalcy-
cler (Bio-Rad Laboratories S.r.l., Segrate Milan, Italy) with the
fluorescence detection system iCycler iQ real time PCR. The
amplification mix contained 1 ml cDNA, 0.3 mM of each primer,
12.5 ml of master mix QuantiTECT SYBR green (Quiagen), and
H2O DEPC, for a final volume of 25 ml. Primers pair and
amplification condition are described in Table 1. Relative
expression was calculated using the delta Cq method. The value
Figure 1. Characterization of homocysteinylated albumin by mass spectrometry. Panel A: ESI-MS of human serum albumin. Panel B: ESI-MS
of homocysteinylated albumin. Inset: magnification on expanded scale of the signal at Da=67805. The family of molecular ions is compatible with
the structures shown in the panel.
doi:10.1371/journal.pone.0031388.g001
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2delta delta Cq.1 reflects increased expression of the relevant
gene, and a value of 2
2delta delta Cq,1 points to a decrease in gene
expression.
For VCAM1 transcript amplification, 2 ml cDNA were
employed and mix was replaced by a mixture containing: 0.5unit
of Taq Polymerase (Fermentas Inc., MD, USA), 0.2 mM each
dNTP, 2 ml buffer, in a 20 ml final volume and reactions carried
out in a Mastercycler gradient (Eppendorf s.r.l., Milan, Italy).
Protein analyses
Western Blot analyses were performed as previously described
[25], using anti-human HSP60 (BD Pharmingen), anti-human
ADAM17 (Abcam), anti-human MCP1 (Santa Cruz), anti-human
ICAM1 (BD Pharmingen) and anti-human CCR2 (Abcam) as
appropriate.
Figure 2. Effects of homocysteinylated albumin on monocyte
adhesion. U937 monocytoid cells adhesion onto an endothelial
monolayer (EAhy926) expressed as adherent cells (number/field; panel
A) and percentage adherent cells compared to positive control (panel
B). Counts are the mean of ten independent experiments, each carried
out by counting five different fields/sample of triplicate samples.
Examples of microscopic fields are shown on the right. C: negative
control (untreated cells); A: unmodified albumin; AH: homocysteiny-
lated albumin; AC: carboxymethylated albumin; T: positive control (Tnf-
a). 0.3 or 1: homocysteine micromolar concentration present in the
assay in the form of N-homocysteinyl groups bound to albumin, as
comparable to the in vivo situation [14]; p,0.0001.
doi:10.1371/journal.pone.0031388.g002
Figure 3. ICAM1 expression in endothelial cells treated with N-
homocysteinylated albumin. Panel A: expression levels of ICAM1
transcripts quantitated by real time PCR (treated: 1 mmol/L homo-
cysteinylated albumin; control: unmodified albumin); (p,0.001). Panel
B: cytofluorimetric analysis of ICAM1 time course surface expression by
EAhy926 endothelial cells treated with homocysteinylated albumin (C:
unmodified albumin negative control; Tnf-a: positive control). Panel C:
Time course of ICAM1 release in the culture medium, quantitated by
ELISA assay. C: negative control (untreated cells); A: unmodified
albumin; AH: 1 mmol/L homocysteinylated albumin; (p,0.001).
doi:10.1371/journal.pone.0031388.g003
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culture media were determined utilizing the relevant ELISA kits
(R&D Systems) according to the supplier’s protocols.
Immunoprecipitation of Hsp60 was performed by magnetic
bead separation using DYNAL Beads (Invitrogen) crosslinked to
anti-human Hsp60 antibody (ABCAM) according to the manu-
facturer. The protein eluted from the crosslinked beads was
revealed by Western blotting.
Cytofluorometric analysis
Cell pellets, harvested and washed with cold PBS containing
0.1% BSA were treated with Phycoeritrine-labeled anti-VCAM1
antibodies or Allophycocyanin-labeled anti-ICAM1 (BD Pharmin-
gen, Milan, Italy) and incubated in ice for 1 h in the dark. At the
end of incubation, 1 ml of cold PBS/0.1% BSA was added and
cells were pelleted. Finally, 500 ml of a PBS/0.1% BSA containing
1 ml of 0.2 mg/ml propidium iodide (Sigma-Aldrich, Milan, Italy)
were added to the cell pellets prior to analysis. cytofluorimetric
analysis was performed in a FACSCalibur (BD Biosciences, Milan,
Italy).
Statistical analysis
An unpaired Student’s t test was performed, to compare means
in the homocysteinylated albumin experiments, or a two-way
ANOVA to assess the timed effects of treatments as appropriate
[26]. All results are presented as the mean (SD). All experiments
were done in triplicate except otherwise stated.
Results
Characterization of homocysteinylated albumin by mass
spectrometry
ESI-MS spectra of unmodified albumin and its homocysteiny-
lated derivative are reported in Fig. 1. The calculated molecular
mass value of native albumin was 66446 Da (Fig. 1; panel A). The
homocysteinylated derivative had a calculated molecular mass of
67805 Da (Fig. 1 panel B, inset) and a calculated mass of
33903 Da for the doubly charged protein (Fig. 1; panel B). The
difference between the homocysteinylated and native species is
equal to 1359 Da. This difference corresponds to the acquisition of
7 N-homocysteinyl moieties (N-Lys-Hcy-SH; 117 Da), which are
Figure 4. VCAM1 expression in endothelial cells treated with N-homocysteinylated albumin. Panel A: Time course of induction of VCAM1
transcripts, in EAhy926 endothelial cells, by treatment with 1 mmol/L homocysteinylated albumin. Panel B: cytofluorimetric analysis of ICAM1 time
course surface expression by EAhy926 endothelial cells treated with homocysteinylated albumin. (C: unmodified albumin negative control; Tnf-a:
positive control). Panel C: Time course of ICAM1 release in the culture medium, quantitated by ELISA assay. C: negative control (untreated cells); A:
unmodified albumin; AH: 1 mmol/L homocysteinylated albumin. (p,0.001).
doi:10.1371/journal.pone.0031388.g004
Table 2. Upregulated genes from transcriptional analysis of EAhy926 cells treated with homocysteinylated albumin compared to
control.
GENE NAME AND FUNCTION GENE SYMBOL Accession number Fold change
Tissue Factor Pathway Inhibitor isoform a TFP1 215447_at 4.972
NADH Dehydrogenase subunit 5 MTND5 1553575_at 4.762
Dehydrogenase/Reductase member 2 isoform 2 DHRS2 214079_at 4.711
Neuropilin1 NRP1 234072_at 4.178
Spectrin Repeat Containing Nuclear Envelop 1 SYNE1 244144_at 3.758
Insulin-like growth factor 1 receptor IGF1R 203628_at 3.598
Secretogranin V, Variant 1 SCG5 203889_at 3.441
Xenotropic/Polytropic Retrovirus Receptor, var 1 XPR1 244755_at 3.331
Transmembr. coiled-coin domain family 1, var 3 TMCC1 237943_at 2.788
ADAM17 metalloprotease ADAM17 205745_x_at 2.664
Tau Tubulin Kinase 2 TTBK2 231610_at 2.664
Mitochondrial Ribosomal Protein S28 MRPS28 236955_at 2.609
Dehydrogenase/Reductase member 2, var 3 DHRS2 206463_s_at 2.581
Solute Carrier Family 25, member 45, var 1 SLC25A45 1563498_s_at 2.497
RAS p21 protein activator 2 RASA2 206636_at 2.474
Polypyrimidine tract binding protein 2 PTBP2 236962_at 2.446
par-3 partitioning defective 3 homolog B, var B PARD3B 244586_x_at 2.387
mucin20, cell surface associated, var S MUC20 226622_at 2.374
UDP-glucose ceramide glucosyltransferase UCGC 204881_s_at 2.265
PAP associated domain, var 1 MTPAP 238706_at 2.241
Chemokine (C-C motif) ligand 2 CCL2 216598_s_at 2.236
ubinuclein 2 UBN2 238350_at 2.140
Heat shock protein 60 kD HSPD1 200806_s_at 2.005
Homocysteinylated albumin concentration was comparable to that detected in vivo in hyperhomocysteinemic uremic patients compared to control.
doi:10.1371/journal.pone.0031388.t002
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plus 4 S-homocysteinyl moieties (N-Lys-Hcy-S-S-Hcy; 133 Da),
linked to N-linked homocysteine, through an S-S linkage [11,28–
30]. This result is highly consistent with what previously reported
[27] except that the S-linked species could not be detected in this
report, since the thiol groups in the N-homocysteinylated protein
derivative were blocked by iodoacetamide (we omitted this step in
order to prevent possible non-physiological toxic effects to cell
cultures). On the other hand the reactivity of the free thiol group
of the N-linked homocysteinyl moiety has been amply established
by previous work [11,28–30].
Effects of treatment of EAhy926 monolayer with
homocysteinylated albumin on monocyte adhesion
Results are presented both as the mean of adherent monocyte
number per field (Fig. 2A), and as percent of adhesion with respect
to the Tnf-a treated positive control (100% adhesion) (Fig. 2B).
Examples of adhesion assay presentation are also given (Fig. 2C).
Results showed that treatment of endothelial cells with
Homocysteinylated albumin at concentrations comparable to
those detected in vivo in uremic hyperhomocysteinemic patients
[14] is followed by a significant increase of monocyte adhesion
onto the endothelial monolayers. Conversely, treatment with
Homocysteinylated albumin, at concentrations comparable to
those detected in vivo [14] in normal subjects, does not result in any
significant increase of adhesion with respect to control treatments.
Homocysteinylated albumin treatment increases
adhesion molecule expression
Cell adhesion and endothelial damage are increased in uremia
and paralleled by time-dependent VCAM-1 and ICAM-1 up-
regulation [31,32].
Fig. 3 and 4 show the results of ICAM1 and VCAM1 kinetic
monitoring in Eahy926 treated with 1.0 mmol/L homocysteiny-
lated albumin compared to control at both gene expression and
protein levels. ICAM1 transcripts significantly increased after
1.0 mmol/L homocysteinylated albumin treatment, compared to
control (Fig. 3A). Consistently, a significant increase in the surface
expression of ICAM1 protein became evident within 18 h
treatment (Fig. 3B), paralleled by ICAM1 release in the medium
(Fig. 3C), thus mirroring the situation detected at cell surface level.
After only 2 h of treatment, as shown in Fig. 4A, the VCAM1
transcripts could be detected, and decline thereafter. This indicates
that homocysteinylated albumin elicits an immediate response in
the regulation of this particular gene. Also VCAM1 antigen
exposure could be detected at high levels on cell surface at 18 h of
treatment with homocysteinylated albumin (Fig. 4B). Consistently,
a parallel increase in VCAM1 protein released in the medium
could be also detected in the culture medium of cells treated with
homocysteinylated albumin, compared to control (Fig. 4C).
Homocysteinylated albumin treatment determines
increased expression in specific mediators of endothelial
cell activation and damage. We were then prompted to
investigate the alterations induced by homocysteinylated albumin
on endothelial monolayers, which may explain the increased
tendency of monocytoid cells to adhere. To this purpose we
employed a genome-wide transcriptional analysis using microarray
hybridization. RNA samples, extracted from endothelial cells
treated with 1 mmol/L homocysteinylated albumin, untreated
albumin, and untreated cells, were utilized. Treatment with
homocysteinylated albumin significantly modifies gene expression
profile of endothelial cells compared to control. In particular,
among the twenty-three up-regulated genes, five are possibly
implicated in endothelial activation (CCL2, HSPD1, ADAM17,
TFP1, NRP1) (Table 2). Validation by real time PCR was carried
out for MCP1, HSPD1, ADAM17, TFP1, NRP1, in consideration
of their possible involvement in vascular remodeling processes.
The increase of transcript levels, upon treatment with 1 mmol/L
homocysteinylated albumin, was confirmed for all these five genes
of interest (Fig. 5).
Among the up-regulated genes identified in the transcriptional
profile of endothelial cells treated with 1.0 mmol/L homocystei-
nylated albumin, we identified three genes deserving special notice
for their involvement in vascular activation and damage: CCL2,
ADAM17, and Hsp60. Transcriptional increase of all these genes
(real time PCR), as well as the levels of the relevant protein
products (ELISA and/or western blot), were also kinetically
monitored.
A time-dependent increase in MCP1 transcription levels could
be observed, in Eahy926 treated with 1.0 mmol/L homocysteiny-
lated albumin with a maximum at 18 h (Fig. 6A). Consistently,
ELISA assays showed a significant increase in MCP1 secreted by
treated cells (Fig. 6B).
The transcript of ADAM17 is subject to time-dependent
increase upon treatment of endothelial cells with 1.0 mmol/L
homocysteinylated albumin (Fig. 6A). In addition, protein levels
were analyzed using an antibody capable of recognizing the two
forms, the precursor (110 kDa) and the mature form (80 kDa), of
ADAM17 and, as shows in Fig. 6C, an increase of both ADAM17
forms could be observed, which was particularly evident in the
case of the mature form. Consistently, we also found a release of
Tnf-alpha in the culture medium of cells treated with homo-
Figure 5. Validation by Q-PCR of transcriptome results relevant
to upregulated gene involved in endothelial dysfunction. A:
unmodified albumin; AH: homocysteinylated albumin. Gene expression
in the AH sample group was significantly increased with respect to the
corresponding genes in the A sample group (p,0.001).
doi:10.1371/journal.pone.0031388.g005
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the controls.
Hsp60 transcription levels also increased, in a time-dependent
fashion, with a similar peak at 18 h (Fig. 6A). In consideration of
the prevalent intracellular localization of Hsp60 antigen, we
evaluated Hsp60 with Western blotting on endothelial cell
extracts. Hsp60 is normally segregated within the intracellular
compartment. We showed, by immunoprecipitation, that, upon
stimulation with homocysteinylated albumin, Hsp60 increased
within the intracellular compartment, paralleled by a time-
dependent release of Hsp60 in the medium (Fig. 6C).
Homocysteinylated albumin treatment determines
increased expression in specific mediators on U937
Cell adhesion involves changes which occur both at the
endothelial and monocyte levels. We were then prompted to
investigate the alterations induced by homocysteinylated albumin
on monocyte U937 cell line, under conditions in which we
observed an increased cell adhesion to endothelial monolayers
treated with homocysteinylated albumin. We then analyzed the
expression levels and the relevant protein levels of three important
markers of monocyte activation, ICAM1, MCP1 and CCR2.
U937 treated with homocysteinylated albumin 1.0 mmol/L
showed a significant increase both of mRNA levels (Fig. 7A) and
protein levels (Fig. 7B) of ICAM1, MCP1 and CCR2, thus
confirming that the observed increase in monocyte adhesion, upon
treatment with homocysteinylated albumin, occurs through up-
regulation of some typical mediator molecules of monocyte
activation.
Discussion
We investigated the effects of homocysteinylated albumin
treatment on monocyte adhesion in a human endothelial cell co-
culture system and relevant biomolecular alterations. We observed
increased monocyte adhesion onto the endothelial monolayers,
concomitantly with up-regulation of ICAM-1 and VCAM-1 after
treatment with homocysteinylated proteins. It has been previously
shown that high homocysteine modifies gene expression in
cultured cells [33–35] and in vivo in animal models [36] and in
humans [37]. In our present model, both endothelial and
monocytoid cells showed, after treatment, a significant, specific
and time-dependent increase, at both transcriptional and protein
levels, of genes potentially involved in vascular remodeling
processes: i.e. ADAM17, MCP1, Hsp60 as schematically summa-
rized in Fig. 8.
ADAM17 is a metalloproteinase involved in the shedding of
adhesion molecules, e.g. ICAM1 [38] and Tnf-a release [39].
Transcriptional up-regulation of ADAM 17 was accompanied by
an increase of its mature form, and, consistently, of Tnf-a released
in the cell medium. ADAM17 activation is also consistent with the
increase of ICAM1 released in the medium of treated cells.
Hyperhomocysteinemia has been hypothesized to be an indicator
of oxidant stress [40]. Moreover homocysteinylated, oxidized
LDL-dependent increase of reactive oxygen species in the
endothelium has been shown [41]. Consistently, we may
hypothesize that, in our model of hyperhomocysteinemia, high
homocysteinylated albumin may contribute to activation of
ADAM17 through the chemical displacement of the pro-domain
in the cysteine switch of this protein [42].
We also detected an up-regulation of MCP1, a protein
belonging to type CC chemokine family, that mediates monocyte
recruitment in proximity of endothelial lesions, by creating of a
chemotactic gradient towards the inflammatory site. Consistently,
we found a significant increase of MCP1 in the medium of treated
cell, compared to controls.
Homocysteinylated albumin treatment also determined a
transcriptional up-regulation of Hsp60, together with its protein
product. Hsp60 was increased both at the cellular level and in the
extracellular medium. Heat shock proteins regulate maintenance
Figure 6. Time-dependent, increased expression of ADAM17, MCP1 and Hsp60 in endothelial cells upon homocysteinylated
albumin treatment. Panel A: Real time PCR evaluation during time course of ADAM17, MCP1 and Hsp60 mRNA. Panel B: ELISA assay of MCP1
released in the culture medium of treated cells. Panel C: Western blotting analysis of intracellular levels of ADAM17, and Hsp60, and analysis of Hsp60
released in the medium by immunoprecipitation and western blotting (Hsp60 IP). A: unmodified albumin control; AH: homocysteinylated albumin
treatment. Levels of transcripts or proteins in the homocysteinylated albumin sample group were significantly increased compared to control
(p,0.001).
doi:10.1371/journal.pone.0031388.g006
Figure 7. Increased expression of ICAM1, MCP1 and CCR2 in U937 upon homocysteinylated albumin treatment. Panel A: Real time
PCR evaluation of ICAM1, CCR2 and MCP1 mRNA. Panel B: Western blotting analysis of intracellular levels of ICAM1, CCR2 and MCP1. Levels of both
transcripts and proteins in the homocysteinylated albumin sample were significantly increased compared to control (p,0.001).
doi:10.1371/journal.pone.0031388.g007
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interaction. They can be expressed constitutively or produced in
response to various types of cell stress. Hsp60 was shown to be an
important autoantigen in atherosclerosis [43]. Hsp60 overexpres-
sion entails its expression on cell surface and its secretion, favoring
macrophage adhesion and trans-endothelial migration. Such
studies also showed that Hsp60 membrane exposure participates
in the pathogenesis of the endothelial lesions by binding to specific
antibodies, thus eliciting a cytotoxic effect towards the endothe-
lium. Macrophages express Hsp60 ligands and their interaction
induces their activation [44]. Plasma levels of Hsp60 are
significantly higher in subjects with cardiovascular disease with
respect to those without [45].
The alterations we detected in the endothelial cells, in response
to homocysteinylated albumin treatment, were mirrored by
consistent alterations induced in the monocytoid cells. In these
cell components we detected, upon homocysteinylated albumin
treatment, an up-regulation of ICAM1 and MCP1 (which are
known to be produced by activated monocyte to amplify
inflammatory signal reinforcing monocyte recruitment) and
CCR2 (the MCP1 receptor). We previously showed that, in
mononuclear cells of uremic patients on hemodialysis, who are
typically hyperhomocysteinemic, DNA hypomethylation is pres-
ent, with alterations of the expression pattern of methylation-
dependent genes [37].
It has been previously shown that homocysteine is capable of
inducing vascular alterations at endothelial and vascular smooth
muscle cell levels. Hyperhomocysteinemia and hypomethylation
are associated with the activation of growth factors, lipid
deposition, and vascular smooth muscle cell proliferation activa-
tion. High homocysteine triggers a pro-inflammatory state
involving adhesion molecule expression and monocyte recruit-
ment, through NF-kB activation and stimulation of ICAM-1 and
VCAM-1 induction [46,47]. Homocysteine induces in vitro,i n
endothelial and vascular smooth muscle cells, increased expression
of MCP1, of interleukin-8 (IL-8) and their secretion, thus
promoting monocyte adhesion [2–7,48–51]. It has been reported
that hyperhomocysteinemia due to CBS deficiency promotes
monocyte activation and proinflammatory alterations in transgen-
ic mice [52]. However, previous work was often performed
utilizing concentrations of free homocysteine in the high
micromolar or even millimolar range, i.e. up to one order of
magnitude higher than what observed in homocystinuria, the
pathological condition in which the highest levels are reached [2–
7,48–53]. In our present work, for the first time, we treated cells
with high homocysteine mimicking conditions which actually take
place in vivo. In fact we carried out cell treatment with
homocysteinylated albumin (not free homocysteine) and its
concentrations were comparable to the in vivo uremic milieu.
Homocysteine is mainly protein-bound and homocysteinylation
is a widespread post-biosynthetic protein modification regarded as
a major mechanism through which homocysteine induces vascular
alterations. In this respect it has been shown that N-homocystei-
nylated derivatives of both LDL [21] and HDL [54] are detectable
in human plasma, suggesting that homocysteinylation of plasma
lipoproteins occurring in vivo is facilitated by lipoproteins
oxidation, since these oxidized lipoprotein are more susceptible
to homocysteinylation with respect to unmodified lipoproteins. It
has been proposed that protein homocysteinylation could be one
of the principal mediators of homocysteine toxicity [19–21]. We
showed increased plasma protein homocysteinylation in hyperho-
mocysteinemic uremic patients on hemodialysis, which resulted
only partially responsive to homocysteine-lowering therapy [14].
Albumin also mediates protein endocytosis, and is itself internal-
ized, thus determining, under pathological conditions, an
alteration of the expression of cytokines and relevant receptors
[55,56]. Human serum albumin displays altered functional
properties (e.g. towards ligand binding) in consequence of
homocysteinylation [14].
All in all our present data support the hypothesis that
homocysteinylated proteins are neither secondary byproducts
nor a mere biohumoral circulating marker of chronic hyperho-
mocysteinemia. Our data speak in favor of a mechanistic model of
action according to which protein homocysteinylation, rather than
Figure 8. Summary of the effects of homocysteinylated albumin at cellular levels. Concentrations of N-homocysteinylated albumin,
comparable to those detected in vivo [14], were used. Right panel: untreated cells. Left panel: treated cells. Numbers in circle refer to molecular
markers and mediators of increased adhesion detected in the present work. At endothelial cell level. Transcriptional activation of MCP1, Hsp60,
ADAM17 (no 1). Increase of the cleaved form of ADAM17 (no 2). Increased shedding of Tnfa (no 3), ICAM1 and VCAM1 (AM: adhesion molecules;
no 4). Increased intracellular levels and release of Hsp60 (no 5). Increased MCP1 levels and release (no 6). At monocyte level. Transcriptional
activation of MCP1, CCR2 and ICAM1 (no 7). Increased levels of MCP1 (no 8), CCR2 (no 9), ICAM1 (no 10). The prevalent molecular circulating
homocysteine-protein adducts are schematically illustrated in the lower left corner of right panel (see also Fig. 1).
doi:10.1371/journal.pone.0031388.g008
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regulation of inflammatory chemokines which have been directly
related to the pathogenesis of the early steps of atherosclerotic
lesions.
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